Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipidose for chronic endotoxemia in hemodialysis patients
NCT00506454Phase 2Completed
- Sponsor
- Sepsicure, LLC
- Start
- Aug 2007
- Primary completion
- Feb 2008
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in metabolic endotoxemia (ME) comparing Lipidose with Placebo (2 arms). Primary endpoint: Reduction in Endotoxin Levels at 4 weeks. Started Aug 2007; status: completed.
02
Drugs
GR270773
03
Conditions
metabolic endotoxemia (ME)
Beyond the preview
Go deeper on NCT00506454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00506454.